Melat T. Gebru

Melat T. Gebru

Auto-generated profile, based on publicly available information

Melat T. Gebru

Calico Life Sciences LLC, South San Francisco, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
MGMelat T. Gebru
Melat T. Gebru
JAJennifer M. Atkinson
Jennifer M. Atkinson
MYMegan M. Young
Megan M. Young
LZLIJUN ZHANG
LIJUN ZHANG
ZTZhenyuan Tang
Zhenyuan Tang
Hong-Gang WangHong-Gang Wang
Hong-Gang Wang
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistance arises and the initial response to drug treatment that promotes cell survival is unknown. Recent studies show that a transiently maintained subpopulation of drug-sensitive cells, so-called drug-tolerant "persisters" (DTPs), can survive cytotoxic drug exposure despite lacking resistance-conferring mutations. Using RNA sequencing and drug screening, we find that treatment of FLT3 internal tandem duplication AML cells with quizartinib, a selective FLT3 inhibitor, upregulates inflammatory genes in DTPs and thereby confers susceptibility to anti-inflammatory glucocorticoids (GCs). Mechanistically, the combination of FLT3 inhibitors and GCs enhances cell death of FLT3 mutant, but not wild-type, cells through GC-receptor–dependent upregulation of the proapoptotic protein BIM and proteasomal degradation of the antiapoptotic protein MCL-1. Moreover, the enhanced antileukemic activity by quizartinib and dexamethasone combination has been validated using primary AML patient samples and xenograft mouse models. Collectively, our study indicates that the combination of FLT3 inhibitors and GCs has the potential to eliminate DTPs and therefore prevent minimal residual disease, mutational drug resistance, and relapse in FLT3-mutant AML.

18 September 2025 in Cancer Research
Verified
Journal Article
Open access
MGMelat T. Gebru
Melat T. Gebru
THTimothy E. Hoffman
Timothy E. Hoffman
ABAaron Boudreau
Aaron Boudreau
NVNgoc Vu
Ngoc Vu
FHFei Han
Fei Han
DSDavid Stokoe
David Stokoe
Kelch-like ECH-associated protein 1 (KEAP1) is the third most commonly mutated gene in non–small cell lung cancer and is associated with poor prognosis. In this study, we investigated synthetic lethal interaction genes in KEAP1-mutated cancer cells and identified a dependency on UDP–xylose synthase 1 (UXS1), which converts UDP–glucuronic acid (UDP-GlcA) to UDP–xylose in the proteoglycan synthetic pathway. UDP–glucose dehydrogenase (UGDH), a transcriptional target of NRF2 that converts UDP–glucose to UDP-GlcA, was highly expressed in KEAP1-mutant tumors. Upon UXS1 knockdown, depletion of UDP–xylose occurred in both KEAP1-mutant and wild-type cells, whereas UDP-GlcA accumulated to a greater extent in the KEAP1-mutant setting. The resulting shortage of available UDP and other pyrimidines slowed S-phase progression and stalled DNA replication fork marks, causing cells to undergo prolonged cell-cycle exit or apoptosis. Dependency on UXS1 was rescued by knocking out UGDH to prevent UDP-GlcA accumulation and UDP depletion. DNA replication stress in UXS1-depleted cells sensitized them to clinical cell-cycle checkpoint inhibitors. Furthermore, CRISPR screening experiments identified genes that modulate UXS1 dependency. Whereas the liver had the highest normal tissue expression of UGDH, UXS1 knockout in the liver did not result in hepatotoxicity. Taken together, these data demonstrate that UXS1 is a selective dependency in KEAP1-mutant tumors, and loss of UXS1 creates additional therapeutically exploitable vulnerabilities in KEAP1-mutant tumors. Significance: UXS1 loss in KEAP1-mutant cells causes pyrimidine nucleotide depletion, DNA replication stress induction, and ultimately cell-cycle exit that results in tumor stasis, highlighting UXS1 as a potential therapeutic target in KEAP1-mutant tumors. See related commentary by Yasseen and DeNicola, p. 4582

1 December 2025
Verified
Other
Open access
MGMelat T. Gebru
Melat T. Gebru
THTimothy E. Hoffman
Timothy E. Hoffman
ABAaron Boudreau
Aaron Boudreau
NVNgoc Vu
Ngoc Vu
FHFei Han
Fei Han
DSDavid Stokoe
David Stokoe
Critical reagents used with corresponding identifiers

1 December 2025
Verified
Other
Open access
MGMelat T. Gebru
Melat T. Gebru
THTimothy E. Hoffman
Timothy E. Hoffman
ABAaron Boudreau
Aaron Boudreau
NVNgoc Vu
Ngoc Vu
FHFei Han
Fei Han
DSDavid Stokoe
David Stokoe
CRISPR knockout screening reveals additional effectors of sensitivity to UXS1 loss

1 December 2025
Verified
Other
Open access
MGMelat T. Gebru
Melat T. Gebru
THTimothy E. Hoffman
Timothy E. Hoffman
ABAaron Boudreau
Aaron Boudreau
NVNgoc Vu
Ngoc Vu
FHFei Han
Fei Han
DSDavid Stokoe
David Stokoe
UXS1 loss is well tolerated by normal mouse livers, a tissue with high UGDH expression

1 December 2025
Verified
Other
Open access
MGMelat T. Gebru
Melat T. Gebru
THTimothy E. Hoffman
Timothy E. Hoffman
ABAaron Boudreau
Aaron Boudreau
NVNgoc Vu
Ngoc Vu
FHFei Han
Fei Han
DSDavid Stokoe
David Stokoe
Significantly enriched or depleted guides from CRISPR knockout screen